GlaxoSmithKlineE Balance Sheet Health
Financial Health criteria checks 5/6
GlaxoSmithKlineE has a total shareholder equity of EGP1.9B and total debt of EGP518.6M, which brings its debt-to-equity ratio to 26.9%. Its total assets and total liabilities are EGP3.7B and EGP1.8B respectively. GlaxoSmithKlineE's EBIT is EGP582.9M making its interest coverage ratio -5.4. It has cash and short-term investments of EGP212.2M.
Key information
26.9%
Debt to equity ratio
ج.م518.64m
Debt
| Interest coverage ratio | -5.4x |
| Cash | ج.م212.21m |
| Equity | ج.م1.93b |
| Total liabilities | ج.م1.78b |
| Total assets | ج.م3.71b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BIOC's short term assets (EGP3.0B) exceed its short term liabilities (EGP1.7B).
Long Term Liabilities: BIOC's short term assets (EGP3.0B) exceed its long term liabilities (EGP82.5M).
Debt to Equity History and Analysis
Debt Level: BIOC's net debt to equity ratio (15.9%) is considered satisfactory.
Reducing Debt: BIOC's debt to equity ratio has increased from 16.4% to 26.9% over the past 5 years.
Debt Coverage: BIOC's debt is well covered by operating cash flow (23.3%).
Interest Coverage: BIOC earns more interest than it pays, so coverage of interest payments is not a concern.